Email: info@neweastbio.com   |  Call: 6109452007

china-flag-transparent-20

CTC-BIOPSY®-A10

Automatic Circulating Tumor Cell Separator

Previous slide
Next slide

Circulating Tumor Cell Separator


Based on the physical differences such as size, deformability, and fluid dynamics between Circulating Tumor Cells (CTCs,  1 ctc per ml blood) and blood cells, the whole blood is filtered through patented nano-microsieve membrane and then CTCs with Cell diameter over 15 µm are captured and enriched on the membrane.

Cat. #: CTC-BIOPSY-A10

         Applications         
Circulating Tumor Cell (CTC) detection offers advantages such as non-invasive, real-time monitoring. It serves as a powerful tool for guiding personalized treatment in breast cancer patients. CTC testing can replace or complement tissue samples for pathological diagnosis, prognosis assessment, and subtype analysis. Additionally, dynamic CTC monitoring aids in disease progression evaluation and treatment efficacy assessment. CTC counts hold prognostic value for both early-stage and metastatic breast cancer. Notably, in early-stage breast cancer, a CTC count ≥1 signifies the presence of minimal residual disease (MRD) or indicates poorer prognosis.

CTCs can be thought of as a liquid biopsy from the blood. The clinical applications of CTCs include  selection and monitoring of therapeutic regimens; and drug target applications.

CTC Clinical Research Publication Trends (1980-2024)
Mechanism – Separation by Filtration
Utilizing suction filtration technique to separate CTC and CTM from the red blood cells in the whole blood.   CTC and CTM are retained on the membrane.
The membrane is nano-microsieve with 13 mm in diameter.  It has 160,000 micropores. The pore size is uniform (8 um), and the inter-pore distance is also uniform (25 um).  It allows for efficient enrichment of CTCs, making CTCs visible under a regular microscope.
The micro sieve membrane is second-generation nano polymer material.  It is resistance to various staining reagents with good light transmission. It allows us to  directly observe the CTC under microscope.

 

Operation
High automation, 10 mins to complete CTC capture and enrichment of 5ml of the whole blood .
Nano-microscreen technology, no reliance on specific cell marker, suitable for all types of tumors.
CTC Classifications

Circulating Tumor Cell (CTC)

CTCs are found in the blood as either single cells, bound together in tight ‘microclusters’, and/or clustered together with immune cell

Circulating Tumor Microemboli (CTM)

Have  at least 3 CTCs

Play an important role in tumor metastasis. The metastasis risk increases by 23-50 times.

CTC Neutrophil Clusters (Neutrophil CTM)

CTC neutrophil clusters, representing a critical weakness in the metastatic process, the link between neutrophils and CTC drives the progress of cell cycle in the blood flow and expands the metastatic potential of CTC.

The  survival period decreases by 5 times.

Tumor Metastasis Risk: CTC < CTM < Neutrophil CTM

CTC Rarity – 1 per ml of the Whole Blood
Morphological Criteria for CTC Identification

1. Cell diameter (longest side) > 15µm;
2. Nuclear-to-cytoplasmic ratio (NCR) > 0.8;
3. Abnormal nuclear morphology, such as lobulated or mulberry-like nuclei;
4. Hyperchromatic and unevenly stained nuclei;
5. Thickened nuclear membrane with indentations or folds, resulting in an irregular nuclear shape;
6. Presence of giant nucleoli;

※ A single CTC (Circulating Tumor Cell) is defined as meeting 4 or more criteria.
※ A cluster of 3 or more CTCs is referred to as a CTM (Circulating Tumor Microemboli).
※ When a CTM combines with a neutrophil, it is referred to as a Neutrophil CTM. Complying with 4 or more items is considered a single CTC.

CTC pathology detection is the gold standard – classic technology

Images of CTC or CTM from invasive adenocarcinoma, prostate cancer, right lung cancer, lobar invasive adenocarcinoma, adenocarcinoma of gastric fundus, kidney cancer, colon cancer,ulcerative gastric adenocarcinoma, moderately differentiated adenocarcinoma of the rectum, stomach cancer, rectal adenocarcinoma and breast cancer etc.

Downstream Applications of Separated CTCs

IHC

IF

FISH

Cell Culture

      Product Features      
Advantages
High automation, 10 mins to complete CTC capture and enrichment of 5ml of whole blood .
Nano-microscreen technology, no reliance on specific cell marker, suitable for all types of tumors.
No lysis of red blood cells or pre-centrifugation to preserve the CTM intact, direct observation under microscope.
Autonomous downstream analyses, such as IF, IHC, FISH and sequencing to meet the requirements of clinical research.
Superior Performance

Optimized isolation technology by size of epithelial tumor cells (ISET) can accurately and reliably capture abnormal cells in blood, providing a efficient solution for tumor screening.

■ High-risk Tumor screening
■ Companion Diagnosis   ■ Early Warning
Patented ISET Technology

ISET technology uses the size and deformability of tumor cells to achieve separation, then use cell morphology for identification.

■ With good light transmission, second-generation nano polymer material is resistance to various staining reagents, allowing direct observation of cells in visible light.
■ Nano-microsieve technology broke the foreign monoply, high-precision lithography machine for laser lithography.
■ 13mm micro sieve membrane has 160,000 nano micro sieves with an aperture of 8um to maximize the sorting of blood cells and tumor cell enrichment.
Uniform hole spacing
Uniform aperture
Excellent light transmission of membrane
Resistance to various staining reagents
High Detection Rate of CTM

CTC detection data of the CTC-BIOPSY® system in 2018-2020 showed an average CTC detection rate for each tumor is 80.90% ,CTM (Circulating Tumor Microemboli) detection rate is 12.52%, and the ratio of CTM to total CTC detection was consistent with study data from Nature in 2019.

Partial Detection Data of CTC and CTM from 2018 to 2020:

     Publications 
   References 

CTC Clinical References

    Top CTC Companies   
Top Companies in Circulating Tumor Cells Market

Clearbridge Biomedics

Circulating Tumor Cell Separator
(CTC Separation by Filtration)
Antibody Internalization Labeling Kit
Name Brand Lab Supplies
Biosimilar Reference Antibodies
Synthetic Nanodisc
No Acetylation cAMP/cGMP EIA Kits

 

 

A Solution for Real-time Tumor Monitoring
Convenient · Efficient · Accurate

CTC-BIOPSY®-A10

Select by Alphabet
Main Menu

Products

Applications

Technical Supports

Contact

中国武汉办事处

Copyright © 2010-2024 NewEast Biosciences | All rights reserved

GTPase & Oncogene | cGMP & cAMP | Nanobody | Bioactive Transmembrane Proteins | Circulating Tumor Cells | Lipoproteins